Stay updated on BMN 110 Phase 3B in Australian Patients Clinical Trial
Sign up to get notified when there's something new on the BMN 110 Phase 3B in Australian Patients Clinical Trial page.

Latest updates to the BMN 110 Phase 3B in Australian Patients Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe record describes BioMarin’s completed Phase 3B BMN 110 study in Australian patients with MPS IVA, including its treatment plan, eligibility criteria, study locations, and outcome measures.SummaryDifference44%

- Check20 days agoChange DetectedThe site footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide banner announces that NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check34 days agoChange DetectedThe page continues to show a 403 Forbidden error, while the footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now renders a 403 Forbidden error, replacing the study record content. A Home link appears and the detailed study information is no longer accessible.SummaryDifference17%

Stay in the know with updates to BMN 110 Phase 3B in Australian Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BMN 110 Phase 3B in Australian Patients Clinical Trial page.